DeutschNewstral
Article
jdsupra.com on 2017-04-14 18:22
Aragen Bioscience Files Three Petitions for IPR on Cell-Line Patents
Related news
- DOJ Files IPR Petitions Against Discovery Patentsjdsupra.com
- Mylan Files Ten Additional IPR Petitions Challenging Sanofi’s Lantus Patentsjdsupra.com
- Sandoz Files Petitions for IPR on Two Abbvie Adalimumab Patentsjdsupra.com
- Celltrion Files Petitions for IPR of Three Rituximab Patentsjdsupra.com
- Mylan Files Two Petitions for IPR of Sanofi’s Insulin Glargine Patentsjdsupra.com
- Celltrion Files Two Additional Petitions for IPR on Genentech’s Trastuzumab Patentsjdsupra.com
- Celltrion Files Two Additional Petitions for IPR of Genentech’s Trastuzumab Patentsjdsupra.com
- Sandoz Files Two Petitions for IPR of Two AbbVie Patents Related to Humirajdsupra.com
- Pfizer Files Two Petitions for IPR of Chugai Pharmaceutical’s Protein Purification Patentsjdsupra.com
- New IPR Petitions Filed Against GSK Vaccine Process Patentsjdsupra.com
- Challenges in Filing Successful IPR Petitions for Video Game Patentsjdsupra.com
- Why Biotech and Pharma Patents Survive IPRjdsupra.com
- Mylan Files Two Petitions for IPR on Genentech’s Herceptin Patentjdsupra.com
- Board Grants Hospira Mixed Results on its Five Petitions for IPR of Genentech’s Trastuzumab Patentsjdsupra.com
- Mylan Files New IPR Petitions on Aflibercept Patentsjdsupra.com
- Pfizer Files for IPR of Two Biogen Patents Directed to Rituximabjdsupra.com
- Coherus Files Two More Petitions for IPR of Abbvie’s ‘619 Humira Patentjdsupra.com
- Pfizer files two IPR petitions on Genentech’s Patent Directed to Methods of Making Humanized Antibodiesjdsupra.com
- Forum Selection Clause Prohibits Filing IPR and PGR Petitionsjdsupra.com
- Petitioner Must Explain Differences Among Five Concurrent IPR Petitionsjdsupra.com